Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

BACKGROUND: Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Belderbos, Bodine P.S., de Wit, Ronald, Hoop, Esther Oomen-de, Nieuweboer, Annemieke, Hamberg, Paul, van Alphen, Robbert J., Bergman, André, van der Meer, Nelly, Bins, Sander, Mathijssen, Ron H.J., van Soest, Robert J.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739748/
https://ncbi.nlm.nih.gov/pubmed/29290963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22474
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires